
CLAIMS

1. Use of a RXR agonist of Formula I,




(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof in the preparation of a medicament, for treating a patient with $Her2^+$ cancer, and

wherein the patient has received, is receiving, or is scheduled to receive a Her2-targeted therapeutic agent, and wherein the Her2-targeted therapeutic agent is an anti-Her2 antibody or a Her2 kinase inhibitor selected from lapatinib or neratinib.

2. Use of a RXR agonist of Formula I,



(Formula I)


~~Wherein~~ wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof, in the preparation of a medicament for treating a patient with $Her2^+$ cancer, and

wherein ~~said~~the RXR agonist is to be used in combination with a Her2-targeted therapeutic agent, and wherein the Her2-targeted therapeutic agent is an anti-Her2 antibody or a Her2 kinase inhibitor selected from lapatinib or neratinib.

3. The use of any one of claims 1 or 2, wherein a thyroid hormone is to be administered in conjunction with the RXR agonist.

4. The use of claim 3, wherein the thyroid hormone is thyroxine.

5. The use of any one of claims 1-4, wherein the RXR agonist is a compound of Formula II



(Formula II).

~~6. The use of any one of claims 1-5 wherein an anti-Her2 therapeutic antibody is to be further administered.~~

~~7~~6. The use of any one of claims 1-5 ~~6~~, wherein the ~~therapeutic~~ anti-Her2 antibody is trastuzumab or pertuzumab.


~~8~~7. The use of any one of claims 1-5, wherein the Her2-targeted therapeutic agent is an antibody-drug conjugate ~~is to be further administered, wherein the antibody is an~~ comprising the anti-Her2 antibody.

~~9~~8. The use of claim ~~8~~7, wherein the antibody-drug conjugate is ado-trastuzumab emtansine.

~~10. The use of any one of claims 1-9, wherein a Her2 kinase inhibitor is to be further administered.~~

~~11. The use of claim 10, wherein the Her2 kinase inhibitor is lapatinib or neratinib.~~

~~12~~9. A combination comprising a Her2-targeted therapeutic agent and a RXR agonist of Formula I,




(Formula I)

~~Wherein~~ wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof; and

wherein the Her2-targeted therapeutic agent is an anti-Her2 antibody or a Her2 kinase inhibitor selected from lapatinib or neratinib.

~~13~~10. The combination of claim ~~12~~9, further comprising thyroid hormone.

~~14~~11. The combination of claim ~~12~~9, wherein the RXR agonist is a compound of Formula II



(Formula II).

~~15~~12. The combination of claim ~~12~~9, wherein the ~~Her2-targeted therapeutic agent comprises an~~ anti-Her2 ~~therapeutic~~ antibody is selected from trastuzumab or pertuzumab.

~~16~~13. The combination of claim ~~12~~9, wherein the ~~Her2-targeted therapeutic agent comprises~~Her2-targeted therapeutic agent is an antibody-drug conjugate ~~wherein~~ comprising the ~~antibody is an~~ anti-Her2 antibody~~. comprising ado-trastuzumab emtansine.~~

14. The combination of claim 13, wherein the antibody-drug conjugate is ado-trastuzumab emtansine.

~~17. The combination of claim 12, wherein the Her2-targeted therapeutic agent comprises a Her2 kinase inhibitor selected from lapatinib or neratinib.~~